Medicenna Therapeutics Corp (MDNA) AI Stock Analysis

• Market Cap: C$70.39M
• Dividend Yield: N/A
• Average Volume (3M): 47.98K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.52
• Revenue Growth: N/A
• EPS Growth: -67.03%
• Country: CA
• Employees: 16
• Sector: Healthcare
• Sector Strength: 77
• Industry: Biotechnology
• EPS (TTM): -0.37
• Shares Outstanding: 78,215,750
• 10 Day Avg. Volume: 20,071
• 30 Day Avg. Volume: 47,984
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -3.50
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$3.61
• Price Target Upside: 288.17% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

Medicenna Therapeutics Corp.'s overall score reflects financial and technical challenges, underscored by negative cash flows and bearish technical indicators. However, the company's low debt levels and recent positive corporate developments, including promising clinical trial results, offer some optimism for future potential. Valuation remains difficult due to negative earnings.

Positive Factors

Clinical Trials

Encouraging responses were observed in the combination arm for patients who do not typically benefit from immunotherapy.

Financial Stability

The cash runway for Medicenna Therapeutics extends into mid-calendar 2026, supporting its financial stability.

Negative Factors

Efficacy Uncertainty

Although the combo data is promising, it is too early to determine efficacy.

Response Rate

The overall response rate (ORR) for the Medicenna pembro combo in solid tumors is low at 22%.

Medicenna Therapeutics Corp Business Overview & Revenue Model

Company Description

Medicenna Therapeutics Corp (MDNA) is a clinical stage immunotherapy company that operates in the biotechnology sector, focusing on the development of novel, highly selective engineered cytokines called 'Superkines' and first-in-class Empowered Cytokines for the treatment of cancer. The company is dedicated to advancing these innovative therapies to address unmet medical needs and improve patient outcomes in oncology.

How the Company Makes Money

Medicenna Therapeutics Corp generates revenue primarily through strategic partnerships, collaborations, and licensing agreements with other pharmaceutical and biotechnology companies. These partnerships often involve the co-development, commercialization, or out-licensing of their proprietary therapeutic candidates, which can lead to upfront payments, milestone payments, and royalties based on product sales. Additionally, the company may receive funding through grants and research contracts to support its development programs. As a clinical-stage company, Medicenna does not yet have commercialized products generating direct sales revenue.

Medicenna Therapeutics Corp Financial Statement Overview

Summary

Medicenna Therapeutics Corp. exhibits financial challenges typical for early-stage biotechnology firms, with ongoing net losses and negative cash flows. While the balance sheet suggests some stability due to low debt levels, the company's financial health depends on improving revenue generation and achieving positive cash flows.

Income Statement

Medicenna Therapeutics Corp. shows a challenging income statement with negative EBIT and net income over the TTM period, reflecting ongoing financial struggles. Revenue generation remains minimal, with a recent TTM revenue of $5,000. However, there is a notable improvement in gross profit margin for the TTM, suggesting potential for efficiency gains.

Balance Sheet

The balance sheet indicates moderate stability with a favorable equity ratio due to relatively high stockholder equity compared to total assets. The company's debt-to-equity ratio is low, reflecting prudent debt management. However, there is a reduction in stockholder equity over time, which could affect financial flexibility.

Cash Flow

Cash flow analysis reveals negative free cash flow, a significant concern for sustainability. The firm relies heavily on financing activities to support operations, which is not sustainable in the long term. There is a lack of positive operating cash flow, indicating ongoing cash management challenges.

Breakdown
TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
5.00K	0.00	0.00	0.00	0.00	0.00
	Gross Profit
4.00K	-5.00K	-5.00K	-38.00K	-40.00K	―
	EBIT
-8.04M	-19.66M	-21.64M	-22.30M	-17.19M	-8.21M
	EBITDA
-18.65M	-18.67M	-16.30M	-22.54M	-17.25M	-8.27M
	Net Income Common Stockholders
-26.90M	-25.47M	1.55M	-22.65M	-17.18M	-8.31M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
30.00M	16.98M	33.60M	20.54M	40.38M	37.70M
	Total Assets
32.24M	19.13M	36.45M	23.46M	42.25M	38.00M
	Total Debt
174.00K	0.00	0.00	0.00	34.00K	67.31K
	Net Debt
-29.82M	-16.98M	-33.60M	-20.54M	-30.34M	-22.63M
	Total Liabilities
14.79M	13.94M	6.96M	2.62M	4.11M	1.85M
	Stockholders Equity
17.45M	5.19M	29.49M	20.84M	38.15M	36.15M
Cash Flow		Free Cash Flow
-16.37M	-16.26M	-12.66M	-23.58M	-15.31M	-8.95M
	Operating Cash Flow
-16.34M	-16.26M	-12.66M	-23.58M	-15.31M	-8.95M
	Investing Cash Flow
-33.00K	0.00	-13.05M	10.05M	5.01M	-15.00M
	Financing Cash Flow
23.51M	0.00	24.76M	3.88M	18.26M	44.28M

Medicenna Therapeutics Corp Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.93
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MDNA, the sentiment is Negative. The current price of 0.93 is below the 20-day moving average (MA) of 1.00, below the 50-day MA of 1.11, and below the 200-day MA of 1.74, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 35.41 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MDNA.

Medicenna Therapeutics Corp Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KPT	59 Neutral	C$78.15M	32.06	3.53%	9.21%	―	―
Sector *	48 Neutral	$6.35B	1.19	-46.87%	2.63%	17.16%	1.34%
ONC	47 Neutral	$60.50M	―	-184.69%	―	―	0.10%
MDNA	42 Neutral	C$70.39M	―	-149.09%	―	―	-67.03%
SLS	31 Underperform	$677.43M	―	-9999.00%	―	―	-69.63%

Medicenna Therapeutics Corp Corporate Events

Medicenna to Present at Healthcare Innovation Conference

Medicenna Therapeutics Corp announced that its President and CEO, Dr. Fahar Merchant, will present at the Jones Healthcare and Technology Innovation Conference in Las Vegas. This participation highlights Medicenna’s active engagement with investors and industry stakeholders, potentially enhancing its visibility and strategic positioning in the immunotherapy sector.

Medicenna to Present Key Updates at AACR 2025

Medicenna Therapeutics Corp announced that it will present updates from its Phase 1/2 ABILITY-1 Study of MDNA11 and pre-clinical data for MDNA113 at the upcoming American Association for Cancer Research Annual Meeting 2025. These presentations highlight Medicenna’s progress in developing innovative cancer therapies, potentially enhancing its position in the immunotherapy market and offering new treatment options for patients with advanced solid tumors.

Medicenna’s MDNA11 Shows Promising Results in Cancer Treatment

Medicenna Therapeutics Corp has announced promising results from its ABILITY-1 study, showcasing the potential of its MDNA11 therapy in combination with Merck’s KEYTRUDA® for treating advanced solid tumors. The study revealed that MDNA11 significantly expands stem-like CD8+ T cells, leading to a 30% objective response rate in checkpoint-resistant patients and a 78% disease control rate when combined with KEYTRUDA®. These findings suggest that MDNA11 could enhance the efficacy of immune checkpoint inhibitors and improve outcomes for patients with difficult-to-treat cancers.

Medicenna Reports Promising ABILITY-1 Trial Results and Strong Financial Position for 2025

Medicenna Therapeutics Corp announced its financial results for the third quarter of fiscal 2025, highlighting significant progress in its ABILITY-1 trial, which combines MDNA11 with KEYTRUDA. The trial demonstrated a 78% disease control rate with promising responses, including complete and partial responses in patients with treatment-refractory tumors. The company also reported strong financial backing, ensuring operations are funded through mid-2026, and shared its excitement about upcoming milestones that could further validate its clinical development program.

Medicenna to Engage Investors at February 2025 Conferences

Medicenna Therapeutics Corp announced its participation in two key investor conferences in February 2025, where it seeks to engage with investors through presentations and one-on-one meetings. This strategic move aims to elevate the company’s visibility and strengthen its position in the biotechnology sector by showcasing their innovative immunotherapy developments.